Oncogenic Kras activates a plethora of signaling pathways, but our understanding of critical Ras effectors is still very limited. We show that cell-autonomous phosphoinositide 3-kinase (PI3K) and 3-phosphoinositidedependent protein kinase 1 (PDK1), but not Craf, are key effectors of oncogenic Kras in the pancreas, mediating cell plasticity, acinar-to-ductal metaplasia (ADM), and pancreatic ductal adenocarcinoma (PDAC) formation. This contrasts with Kras-driven non-small cell lung cancer, where signaling via Craf, but not PDK1, is an essential tumor-initiating event. These in vivo genetic studies together with pharmacologic treatment studies in models of human ADM and PDAC demonstrate tissue-specific differences of oncogenic Kras signaling and define PI3K/PDK1 as a suitable target for therapeutic intervention specifically in PDAC.
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is nearly uniformly fatal despite maximal treatment, with fewer than 1% of patients surviving 5 years (Carpelan-Holmströ m et al., 2005) . A wealth of molecular studies have identified mutant Kras as the initiating event (Hidalgo, 2010; Hingorani et al., 2003; Morris et al., 2010; Pylayeva-Gupta et al., 2011) . Expression of Kras G12D or Kras G12V in the murine pancreas induces acinar cell dedifferentiation, acinar-to-ductal metaplasia (ADM), and premalignant precursor lesions, called pancreatic intraepithelial neoplasia (PanIN) that progress to metastatic PDAC (Guerra et al., 2007; Hingorani et al., 2003; Morris et al., 2010; Pinho et al., 2011; Seidler et al., 2008) . Oncogenic Kras activates a plethora of signaling pathways, including canonical Raf/MEK/ERK, PI3K/AKT, RalGDS/p38 MAPK, Rac and Rho, Rassf1, NF1, p120GAP, and PLC-ε (Castellano and Downward, 2011; Pylayeva-Gupta et al., 2011) . However, which of these effector pathways of oncogenic Kras control cell fate decisions and PDAC formation remains an outstanding question (Morris et al., 2010; Pylayeva-Gupta et al., 2011) . The PI3K/AKT pathway is uniformly activated in human PDAC and mouse models of Kras-driven pancreatic cancer Significance Kras-driven tumors such as PDAC, NSCLC, or colon cancer differ in prognosis and response to targeted therapies. However, the underlying molecular mechanisms are largely unknown. Oncogenic Kras activates diverse signaling pathways but the functional relevance of specific Kras effectors is unclear for most cancer types. Because Kras is considered undruggable, this has hampered progress toward targeted therapeutic interventions. We provide in vivo genetic evidence for context-specific effector pathways of oncogenic Kras in PDAC and NSCLC and define cell autonomous Kras / PI3K / PDK1 signaling as a critical and therapeutically tractable axis in pancreatic cancer initiation and maintenance. (Jimeno et al., 2008; Kennedy et al., 2011; Ying et al., 2011) . PI3Ks are a family of heterodimeric lipid kinases composed of catalytic and regulatory subunits that, on stimulation, catalyze production of the second messenger phosphatidylinositol-3,4,5-triphosphate (PIP3), which activates downstream kinases, such as PDK1 and AKT (Castellano and Downward, 2011; Bader et al., 2005) . p110a, which is encoded by PIK3CA, is the catalytic subunit of the ubiquitously expressed class IA PI3Ka. Hotspot mutations of p110a that activate PI3K signaling have been identified in the helical domain (E542K and E545K) and the catalytic domain (H1047R) in a variety of human cancers, including breast and lung (Bader et al., 2005; Liu et al., 2009) . Transgenic expression of p110a H1047R in mice induces breast and lung cancer (Adams et al., 2011; Engelman et al., 2008; Liu et al., 2011) . Taking advantage of genetically engineered murine and patient-derived humanized cancer models, we set out to analyze the contribution of Kras effector pathways to PDAC and NSCLC development.
RESULTS

Pancreas-Specific PI3K Pathway Activation by Expression of Oncogenic p110a
H1047R Induces ADM and Premalignant PanIN To explore the role of the PI3K/AKT signaling pathway in Krasinduced cell plasticity, ADM, and PDAC formation, we generated a latent oncogenic PIK3CA H1047R (encoding p110a H1047R )
allele silenced by a lox-stop-lox (LSL) cassette as a knock-in at the mouse Rosa26 locus (LSL-PIK3CA H1047R mouse line; Figures S1A-S1C available online). To activate the expression of p110a H1047R and thus PI3K signaling, specifically in the pancreas, we used the well-established Ptf1a Cre driver line to direct recombination in pancreatic acini, ducts, and islets (Figures S1D and S1E) (Nakhai et al., 2007; Seidler et al., 2008; von Werder et al., 2012) . Figure 1D ) (Pinho et al., 2011) . Furthermore, all animals developed PanIN, a precursor lesion of PDAC ( Figure 1D ) (Hruban et al., 2006) . The amount and grade of these lesions increased over time from PanIN-1A, already present in 1-month-old mice, to PanIN-3, found in some 9-month-old animals, which represents carcinoma in situ ( Figures 1D and  1E ). The PIK3CA H1047R/+ and Kras G12D/+ models showed very similar patterns of ADM induction and PanIN progression ( Figures 1D and 1E ) and markers of PI3K pathway activation were almost identical, as shown by immunohistochemistry and western blot analysis of tissue lysates ( Figures 1F and 1G ). Indicators of PI3K signaling, such as proliferation of PanIN lesions, were consistently similar in both models (Figures S1F and S1G). These observations support the view that pancreasspecific activation of PI3K signaling phenocopies Kras G12D -induced cellular plasticity and PanIN formation.
To confirm that acinar cell plasticity via ADM is indeed involved in PanIN and PDAC development, we used an elastase-1 Cre driver line (Stanger et al., 2005) mutant animals revealed striking similarities, with nearly identical survival times and similar rates of metastasis (Figures 2A and S2B) . p110a H1047R -induced tumors were histopathologically indistinguishable from human and murine Kras G12D -induced PDAC and showed the full spectrum of the human disease, ranging from well-differentiated ductal PDAC to undifferentiated tumors and typical metastasis to lymph nodes, liver, and lung ( Figures 2B, S2A , and S2B) (Hruban et al., 2006) .
To explore activation of PI3K signaling in p110a H1047R -and Kras
G12D
-driven pancreatic cancer, we analyzed tissues from these animals using phospho-specific antibodies. Similar activation of the key downstream effectors of PI3K signaling, pAKT-T308, pAKT-S473, and pGSK3b-S9 was observed in both models ( Figures 2C and 2D) Figure S2D ). This accords with previous findings that p110a not bound to the p85 regulatory subunit is unstable and rapidly degraded (Engelman et al., 2008) . Figure S2E ) (Caldwell et al., 2012) . Importantly, these lesions showed concomitant upregulation of both Cdkn2a gene products, p16/Ink4a and p19/Arf, and activation of the p53/p21 Cip1 pathway ( Figures S2E  and S2F ).
In PDAC however, p16/Ink4a and p19/Arf expression is lost as demonstrated previously in the Kras G12D model ( Figure S2F and data not shown) (Bardeesy et al., 2006 -induced PDAC with respect to tumor suppressor usage (Bardeesy et al., 2006) . Accordingly, mimicking loss of heterozygosity of Cdkn2a by inactivation of one allele using floxed Cdkn2a mice (Bardeesy et al., 2006) S2J ). These findings demonstrate the importance of the Cdkn2a tumor suppressor locus for PDAC progression. Interestingly, median survival times were indistinguishable between both heterozygous deletion models, arguing that identical pathways and tumor suppressors operate in p110a H1047R -and Kras G12D -driven PDAC formation.
Taken together, these murine in vivo modeling studies clearly demonstrate that PI3K signaling induces acinar cell plasticity, ADM, PanIN formation, senescence via upregulation of p16/ Ink4a and p19/Arf, bypass of senescence by inactivation of Cdkn2a, and ultimately PDAC formation. during the early stages of human pancreatic carcinogenesis, namely ADM and PanIN formation, remains unclear. To test our hypothesis that the PI3K/AKT pathway is activated in human ADM, PanIN and PDAC, we analyzed key surrogates of PI3K signaling: AKT-T308/S473 and GSK3b-S9 phosphorylation (Figures 3A and 3B) . In accordance with the murine in vivo studies, we observed strong activation of PI3K signaling in tissue microarrays of nearly all human ADM (n = 21), PanIN (n = 32), and PDAC (n = 205) specimens ( Figure 3C ).
In addition, we validated PI3K pathway activation in human PDAC using patientderived primary xenografted tumors, early-passage cell lines, and normal pancreatic tissue ( Figure 3D ). These data suggest that PI3K/ AKT signaling is activated at the earliest stages of tumor evolution in humans and controls pancreatic cell plasticity and carcinogenesis.
Elimination of PDK1 Invariably Blocks Kras-Driven ADM, PanIN, and PDAC In Vivo PI3K activates various downstream effectors by converting phosphatidylinositol (4,5)-bisphosphate (PIP2) into the second messenger PIP3. PIP3 transmits PI3K signals by directly binding to proteins with pleckstrin homology (PH) domains, such as PDK1 and AKT (Cantley, 2002) , targeting them to the cell membrane. In turn, PDK1 activates AKT by threonine 308 phosphorylation (Alessi et al., 1997; Currie et al., 1999) .
To test whether cell autonomous signaling of the direct PI3K downstream target PDK1 is essential for Kras-driven pancreatic plasticity and PDAC formation, we inactivated Pdk1 specifically in the epithelial compartment of the pancreas using floxed Pdk1 mice (Lawlor et al., 2002 (Figures 4A-4D ). Pancreata showed normal weight and morphology with some areas of fatty degeneration in older animals, a common sign of cellular stress due to Kras oncogene expression ( Figures 4B and 4C) Figure 4G ) or PIP3 levels ( Figure S3F ). Importantly, we did not observe hypoplasia or developmental defects of the pancreas, pancreatic islets, and beta cells, or overt hyperglycemia and lethality due to PDK1 inactivation in pancreas epithelia as reported by other groups using different Cre-driver lines and genetic backgrounds ( Figures 4B, 4D , S3D, S3G, and S3H) (Hashimoto et al., 2006; Westmoreland et al., 2009 ). We did however observe impaired glucose tolerance, but this did not progress to diabetes mellitus ( Figures S3D and S3H ).
Besides AKT, PDK1 also transmits PI3K-dependent signals to SGK and S6K. The PDK1 effectors RSK and isoforms of PKC are probably not directly controlled by PI3K (Pearce et al., 2010) . To determine whether PDK1 substrates other than AKT play a role in Kras
-induced pancreatic carcinogenesis, we investigated whether their phosphorylation states were affected by the Pdk1 knockout in vivo. Deletion of Pdk1 in the Kras G12D model blocked PKC, RSK (p90RSK-T359/S363), AKT-T308, and GSK3b-S9 phosphorylation ( Figure S3I ). Notably, we observed considerable variation in the phosphorylation levels of PKC and RSK in Ptf1a
Cre/+ ;LSL-Kras G12D/+ pancreata, whereas AKT and GSK3b phosphorylation was always uniformly present ( Figure S3I ). These results provide biochemical evidence that canonical AKT-dependent signaling downstream of PI3K/PDK1 contributes significantly to the observed effects, although the importance of additional PDK1 substrates and alternate effectors cannot be completely excluded (Pearce et al., 2010) .
PDK1 Is Essential for Kras-Induced Upregulation of p16/Ink4 and p19/Arf
To test our hypothesis that PI3K/PDK1 signaling transmits oncogenic Kras
G12D
-induced failsafe mechanisms, we investigated regulation of p16/Ink4 and p19/Arf in pancreata in which the PI3K signaling pathway had been disrupted (Ptf1a
Cre/+ ;LSLKras G12D/+ ;Pdk1 f/f model, Figure 4F ). PDK1 deficiency significantly reduced p16/Ink4a and p19/Arf induction compared to Ptf1a
Cre/+ ;LSL-Kras G12D/+ animals ( Figure 4H ). These in vivo genetic studies therefore support the view that Kras G12D -dependent oncogenic stress fluxes through PDK1 to induce upregulation of the p16/Ink4a and p19/Arf tumor suppressors. Figures S4A  and S4B ). Deletion of Pdk1 in both models led to complete inhibition of ADM, PanIN formation, and PDAC development, indicating that PDK1 is indeed a central node and essential for pancreatic carcinogenesis in diverse in vivo models ( Figures  S4A and S4B) .
In contrast, deletion of Pdk1 in Kras
-driven NSCLC models had no effect on lung tumor formation (Figures S4C-S4F) . Although both the Kras G12D -driven lung and pancreatic cancer models are on a similar genetic background, it remains possible that subtle differences in the genetic background may affect Kras G12D signaling and engagement of PDK1. We therefore used the elastase-1 Cre driver line that recombines loxP sites in the pancreas and the lung of the same animal ( Figures 5A-5C ). Simultaneous Kras G12D expression in both organs of the same animal induced invasive grade 4 NSCLC and pancreatic tumorigenesis ( Figure 5D ). Pdk1 deletion blocked pancreatic neoplasia completely, whereas NSCLC formation in the same animal was unaffected (Figures 5E and 5F). Importantly, Pdk1 deletion did not affect overall survival in this model. All animals in the tumor watch cohort developed grade 3-4 NSCLC within 600 days ( Figure 5F ) and the number of lung lesions was comparable ( Figure 5G ). These in vivo findings support the view that each tissue has its own unique signaling requirement during Kras oncogene-induced transformation.
Craf Is Dispensable for Kras-Driven PDAC Formation It has recently been shown that Craf is essential for Kras G12D -induced NSCLC (Blasco et al., 2011; Karreth et al., 2011) . To investigate the contribution of Craf in pancreatic carcinogenesis, we inactivated Craf in pancreas epithelium using floxed Craf mice (Jesenberger et al., 2001) . Ptf1a
Cre/+ -induced deletion of
Craf in the Kras G12D -driven PDAC model had no inhibitory effect on tumor development or progression and did not improve mouse survival (Figures 6A-6C Figures 6D-6F ). The possibility that tumors developed due to incomplete Craf deletion can thus be excluded. Signaling via Craf is therefore dispensable for initiation of Kras-driven PDAC, supporting the view that Kras exerts its oncogenic effects in a tissue-specific manner.
Disruption of PDK1 or Inhibition of PI3K Signaling Blocks Murine and Human ADM In Vitro To gain insight into the cellular mechanisms of Kras G12D -PI3K-PDK1-induced transformation, we analyzed early events of pancreatic carcinogenesis. As shown in Figure 4 , deletion of Pdk1 blocks not only PanIN development, but also ADM in the Kras G12D model. ADM has recently been suggested to be an initiating event in human and murine PDAC formation (Aichler et al., 2012; Caldwell et al., 2012; Morris et al., 2010; Reichert and Rustgi, 2011) . Previous studies demonstrated that transforming growth factor a (TGF-a)/epidermal growth factor receptor and Ras activation induces ADM in vitro (Means et Representative H&E or alcian blue (AB) stained microscopic pancreas sections from the same animal. Activation of oncogenic Kras G12D in lung and pancreas using the Ela1-CreER TM driver line induces grade 4 NSCLC and pancreatic neoplasia.
(E) Genetic strategy used to study the role of PDK1 in Kras G12D -driven lung and pancreatic cancer formation in the same animal (left panel (Means et al., 2005) . Consistent with the in vivo data ( Figures 7A and 7B) , we observed that deletion of Pdk1 completely blocked ADM in the presence and absence of TGF-a ( Figures 7C and 7D ;Pdk1 f/f pancreata were equally viable (data not shown), thus excluding differences in cellular vulnerability as a possible cause. ADM was also blocked by the pan class I PI3K inhibitor GDC 0941, the PDK1 inhibitor BX912, the dual pan class I PI3K-mTOR inhibitor NPV-Bez235, and the AKT inhibitor MK-2206 ( Figure 7E) . Interestingly, the RSK inhibitor BI-D1870 had no effect on ADM formation even at concentrations as high as 10 mM ( Figure 7E ). These data confirm our in vivo genetic studies in mice and indicate that disruption of the canonical PI3K-PDK1-AKT, but not the PDK1-RSK axis, blocks ADM and therefore, tumor initiation in the pancreas. To test if our murine model system is relevant to humans, we established primary acinar cell culture from human pancreas and performed functional ADM assays with various PI3K-PDK1-AKT pathway inhibitors ( Figures 7F, 7G , S5A, and S5B). As shown in Figure 7F , TGF-a treatment of human acinar cells induced ADM, as indicated by CK19 staining, with concomitant PI3K pathway activation, as evidenced by AKT-T308 phosphorylation. Treatment with GDC 0941 blocked ADM significantly in a dose-dependent manner and inhibited AKT-T308 phosphorylation and CK19 expression ( Figure S5C) .
Overall, these data support the notion that PI3K/PDK1 signaling is essential for pancreatic cell plasticity and tumor initiation and important to transmit the oncogenic Kras-induced program in the pancreas. However, we cannot completely exclude a role for indirect mechanisms of PI3K activation via alternate effectors such as receptor tyrosine kinases, rather than a direct Kras/PI3K interaction ( To inhibit PI3K signaling in vivo, we used GDC 0941, a potent and selective oral pan class I PI3K inhibitor currently under clinical development (LoRusso et al., 2011; Yuan et al., 2013) . GDC 0941 efficiently inhibited the growth of primary murine Kras Figure S6C ) were orthotopically transplanted into the pancreas of NOD-SCID-IL2Rg mice. After establishment of sizeable tumors, mice were randomized and treated with GDC 0941 or vehicle for 12 days (n = 3 per group). Data represent the mean tumor volumes ± SD (**p < 0.01, Student's t test). See also Figure S6 .
S6A-S6C). To evaluate the in vivo efficacy of GDC 0941 against Kras
G12D
-induced PDAC, KPC mice with established tumors of comparable size were treated for 14 days with vehicle or GDC 0941 at 150 mg/kg/day. GDC 0941 efficiently blocked tumor growth as measured by high-resolution ultrasound and reduced phosphorylation of AKT-T308, a surrogate marker of PI3K signaling via PDK1 (Figures 8B-8D ). All GDC 0941-treated animals displayed stable disease, whereas vehicle-treated animals showed rapid disease progression (Figures 8B and 8C) . Consistent with this, histopathologic analysis showed significantly decreased proliferation of GDC 0941-treated tumors ( Figures 8E and 8F) .
To demonstrate the relevance of the pathway for human pancreatic cancer therapy, we used primary patient-derived PDAC cells transplanted orthotopically into the pancreas of NOD-SCID-IL2Rg (NSG) mice. We observed very similar antitumor effects of GDC 0941 in this humanized PDAC model ( Figures 8G and S6D ). These data strongly suggest that PI3K signaling is also necessary for proliferation and maintenance of established murine and human PDAC and that the PI3K-PDK1-AKT pathway is a promising target for therapeutic interventions.
DISCUSSION
There has been no major breakthrough in the treatment of PDAC in the past 30 years and no effective targeted therapies are available (Hidalgo, 2010) . Nearly all PDAC harbor KRAS mutations, but efforts to develop effective Kras inhibitors have generally failed. It is therefore essential to understand and define the importance of effectors of mutant Kras and to identify nonredundant essential nodes of nononcogene addiction (PylayevaGupta et al., 2011) . Here, we show that PI3K-PDK1 signaling is such a node in Kras-driven pancreatic cancer initiation and maintenance.
It has recently become evident that Craf is essential for the onset of Kras-driven non-small cell lung cancer (Blasco et al., 2011; Karreth et al., 2011) . However, ablation of Craf in our Kras G12D -driven PDAC model had no significant inhibitory effect on tumor development, progression, or survival. This demonstrates that there are substantial tissue-and context-specific differences in Kras effector usage. Such differences may have important clinical implications because they could explain the diverse response to targeted therapies of different tumor types harboring oncogenic KRAS mutations. Indeed, a recent study showed no substantial response of Kras G12D -driven NSCLC toward PI3K-mTOR inhibition in vivo (Engelman et al., 2008) . In contrast, we demonstrate that targeting the PI3K pathway in Kras G12D -driven PDAC efficiently blocks carcinogenesis and tumor progression. Our data thus provide in vivo evidence for the rationale to investigate Kras-driven oncogenic pathways in a tissue-and context-specific manner to characterize the relevant nodes engaged in different tumor entities.
Collisson and colleagues found that oncogenic Braf V600E is capable of inducing PanIN lesions in mice (Collisson et al., 2012) . Using a tamoxifen-inducible transgenic Pdx1-CreER T2 -driver line, they activated a latent Braf V600E allele in the pancreas of adult mice and observed a greater number of PanIN lesions than in the classical Kras G12D model. These data and our findings clearly show that activation or deletion of different Kras-dependent signaling pathways can induce or block PanIN formation in vivo. This argues either for the existence of several distinct routes toward PanIN formation, or an essential crosstalk between the Raf-MEK-ERK and PI3K-PDK1-AKT pathway, which might depend on alternate effectors like receptor tyrosine kinases (Ardito et al., 2012; Ebi et al., 2011; Navas et al., 2012 levels that Kras acts through PI3K-PDK1 to induce pancreatic cancer. This conclusion is further supported using primary human material showing that PI3K signaling is active in human acinar-to-ductal metaplasia, premalignant pancreatic lesions and cancers, and is mechanistically involved in early processes of pancreatic cell plasticity and cancer formation as well as in tumor maintenance. Downward and colleagues showed previously that the Ras-PI3K interaction plays an important role in Ras-induced skin and lung carcinogenesis (Gupta et al., 2007) . They found that disruption of the direct Ras/p110a interaction-by constitutive expression of Pik3ca T208D/K227A in the mouse germline-dramatically reduced the number of Ras-induced papillomas and lung adenomas (Gupta et al., 2007) . It is however unclear to what extent this was mediated by cell autonomous or non-cell autonomous effects in the host. Since p110a is required for angiogenesis (Graupera et al., 2008) , disruption of the Ras-PI3K interaction in the vasculature, immune system, or stroma is likely to contribute significantly to the observed effects in this model. Because PDK1 is a central node of PI3K signaling (Castellano and Downward, 2011) , we evaluated its cell-autonomous role in Kras-induced NSCLC in vivo. Intriguingly, ablation of Pdk1 specifically in the epithelial compartment of the lung using two different recombination strategies had no significant inhibitory effect on Kras G12D -induced NSCLC development and progression. This suggests that PI3K signaling plays an important role in the tumor microenvironment rather than a cell autonomous function during NSCLC formation (Graupera et al., 2008) . This is supported by the observation that Ras-induced NSCLC development is impaired but not completely blocked by constitutive expression of the Pik3ca T208D/K227A in the mouse germline (Gupta et al., 2007) . In contrast to the lung, genetic inactivation of PDK1 in pancreas epithelium using two different Cre-driver lines completely blocked Kras
G12D
-induced neoplastic transformation. These
Cancer Cell
Context-Specific Kras Signaling in PDAC and NSCLC data clearly demonstrate that each tissue has its own and unique cell autonomous signaling requirements during oncogenic transformation. This advance in our understanding of tissue-specific effects of oncogenic Kras may change clinical practice in the future because it clearly shows that results cannot simply be extrapolated from one Kras-driven tumor entity to another. We have defined the tumor cell autonomous Kras-PI3K-PDK1 axis as an essential pathway of pancreatic cancer with the capacity to induce cell plasticity, ADM, PanIN, and cancer formation as well as tumor maintenance. A large variety of pharmacologic inhibitors directed against the PI3K pathway and the promising targetable node PDK1 are now available for clinical investigation (Engelman, 2009; Liu et al., 2009; Pearce et al., 2010) . Recognition of the importance of the PI3K-PDK1 pathway in PDAC, as demonstrated in this study, will provide a more effective approach for targeted therapeutic interventions for this grave disease.
EXPERIMENTAL PROCEDURES
Mouse Strains and Tumor Models LSL-Kras G12D/+ (Hingorani et al., 2003) , Ptf1a Cre/+ Nakhai et al., 2007; Seidler et al., 2008) , LSL-Rac1 G12V/+ (Srinivasan et al., 2009 ),
LSL-Trp53
R172H/+ (Hingorani et al., 2005) , Trp53 f/+ (Jonkers et al., 2001 ),
LSL-R26
lacZ/+ , R26 mT/mG (Muzumdar et al., 2007) , Ela1-CreER TM (Stanger et al., 2005) , Cdkn2a f/+ (Aguirre et al., 2003) , Craf f/+ (Jesenberger et al., 2001) , and Pdk1 f/+ (Lawlor et al., 2002) mice have been described previously. The strains were interbred to obtain mice with activation of distinct pathways in the pancreas as previously described . All animal studies were conducted in compliance with European guidelines for the care and use of laboratory animals and were approved by the Institutional Animal Care and Use Committees (IACUC) of Technische Universitä t Mü nchen, Regierung von Oberbayern and UK Home Office.
Human Pancreatic Tissue Samples
This study conformed to the Declaration of Helsinki and was approved by the ethics committee of the Technische Universitä t Mü nchen. Informed consent was obtained from all patients included in the study.
Generation of Primary Human and Murine Ductal Pancreatic Cancer Cell Lines
Primary dispersed murine pancreatic cancer cells were established from Ptf1a
Cre/+ ;LSL-Kras G12D/+ and Ptf1a Cre/+ ;LSL-PIK3CA H1047R/+ mice and cultivated as previously described (von Burstin et al., 2009) . Primary dispersed human PDAC cells were isolated from surgically resected human PDAC as recently described (Conradt et al., 2011) . Only early-passage (passage 3 to 4) dispersed cells were used for assays.
Establishment of Patient-Derived Xenograft Tumors from Primary
Human PDAC Tissues were placed into chilled sterile RPMI 1640 (Thermo Scientific/Hyclone, Waltham, MA) supplemented with 1% (v/v) penicillin/streptomycin/amphotericin B. The tumor was washed twice, dissected into 3 mm cubes and pieces were implanted subcutaneously into NOD SCIG IL2Rg (NSG) mice (#005557; Jackson Laboratory, Bar Harbor, Maine) within 1 hour of resection.
Patient-Derived Orthotopic Human Pancreatic Cancer Xenotransplantation Model
One million patient-derived primary human pancreatic cancer cells in 20 ml Dulbecco's modified Eagle medium were implanted orthotopically into the pancreas of NSG mice as described (von Burstin et al., 2009; von Burstin et al., 2008) .
Statistical Analyses
Comparisons between data sets were made with analysis of variance, followed 
